OR WAIT null SECS
DOLLAR RX
October 21, 2026
Video
Experts discuss remibrutinib, the first FDA-approved therapy for symptomatic dermographism, and its role in chronic inducible urticaria.
September 23, 2026
Friedman outlines how dermatologists can track cumulative corticosteroid exposure, identify at-risk patients, and improve patient adherence with handouts.
September 13, 2026
Article
Adam Friedman, MD, breaks down how to say no strategically in dermatology, from delaying an answer to sharing the decision with the requester.
August 29, 2026
Adam Friedman, MD, traces dermatology's yes-first culture to residency competition, previewing an unrehearsed LEADderm 2026 negotiation exercise.